Clinical trials: Skin Cancer Scalp
Actinic Keratosis
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.
- Trial name
- NCT01475955
- Testing
- Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation
- Where
- 13 sites in United States
- Volunteers
- 235 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratoses
PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK
Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin)…
- Trial name
- SESAME 2 (NCT03511326)
- Testing
- Methyl Aminolaevulinate 16% Cream
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Actinic Keratosis (AK)
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
This is a phase 4, multi-centre, randomized, two group, open label, active controlled, parallel group, 17 week trial.
- Trial name
- NCT02406014
- Testing
- Ingenol Mebutate Gel, 0.015%, Diclofenac sodium gel 3%
- Where
- Germany
- Volunteers
- 502 people
- Sponsor
- LEO Pharma
Actinic Keratosis of Face and Scalp
Evaluation of a Topical Treatment for Actinic Keratosis
A topical treatment applied twice daily for 4 weeks to induce disappearance of facial actinic keratosis (AK). First 4 weeks treatment (visit 1, 2 and 3 at 0,2 an 4 weeks) treated as a double blind parallel study.
- Trial name
- NCT01921907
- Testing
- AD17137 topical treatment
- Where
- Israel
- Volunteers
- 52 people
- Sponsor
- Assuta Hospital Systems
Actinic Keratosis
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
The purpose of this study is to compare the efficacy of Photodynamic Therapy (PDT) with methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the the LED light source Aktilite CL128, in treatment of patients with…
- Trial name
- NCT00306800
- Testing
- Photodynamic therapy with methyl aminolevulinate cream
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Galderma R&D
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the…
- Trial name
- NCT03285490
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Breast Cancer, Breast Cancer Stage I
Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
This study is being done to determine if using the Paxman Scalp Cooling System at temperatures lower than the current standard is a safe and tolerable approach to prevent hair loss in breast cancer patients receiving chemotherapy.
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT04180579
- Testing
- PAXMAN Scalp Cooler
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Keratosis, Actinic
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
Guidelines for photodynamic therapy (PDT) of actinic keratosis recommend pretreatment with curettage. The impact of curettage on the treatment effect is, however, not known.
- Trial name
- NCT03697590
- Testing
- No curettage, Curettage
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Bispebjerg Hospital
Alopecia, Chemotherapy-induced Alopecia
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer.
- Conditions
- Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer
- Trial name
- NCT05484973
- Testing
- AMMA Portalbe Scalp Cooling System
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Cooler Heads Care Inc.
Actinic Keratosis
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
The purpose of this study was to compare the efficacy of Photodynamic Therapy (PDT) with methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the Light-emitting diode (LED) light source Aktilite CL128, in treatment…
- Trial name
- NCT00304239
- Testing
- Metvix-PDT, Vehicle-PDT
- Where
- 11 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Galderma R&D
Alopecia
EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors
This study aims to evaluate the Impact of a topical Lotion, CG428, on permanent chemotherapy induced hair and scalp disorders in Cancer survivors.
- Trial name
- VOLUME (NCT02605629)
- Testing
- CG428
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Samsung Medical Center
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Scalp Cooling in MBC
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab…
- Trial name
- NCT04986579
- Testing
- Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Dana-Farber Cancer Institute
Actinic Keratosis (AK)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.
- Trial name
- NCT01926496
- Testing
- Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5%
- Where
- 46 sites in France, Germany and 1 more
- Volunteers
- 485 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the face or the scalp.
- Trial name
- LEIDA (NCT00777127)
- Testing
- Imiquimod, Diclofenac
- Where
- 26 sites in Austria, France and 1 more
- Volunteers
- 258 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
To compare the efficacy and safety profiles of Teva's Diclofenac Sodium Gel, 5% (test product) to Solaraze® (diclofenac sodium) Gel, 3% (reference product) to demonstrate the clinical equivalence and to show that the efficacy of…
- Trial name
- NCT02611804
- Testing
- Diclofenac sodium
- Where
- 30 sites in United States
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp.
- Trial name
- LEIDA 2 (NCT01453179)
- Testing
- Imiquimod, Diclofenac
- Where
- 17 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Alopecia, Breast Cancer
Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has been recently described. This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent persistent alopecia in breast…
- Trial name
- NCT00515762
- Testing
- elasto-gel cap
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Hospital San Carlos, Madrid
Actinic Keratosis
Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp
The purpose of this study is to see how well DFD-07 works in treating actinic keratosis on the face and scalp during 8 weeks of treatment. The study will also look at any unwanted effects of the study drug.
- Trial name
- NCT02654717
- Testing
- DFD-07 Cream
- Where
- 3 sites in Germany
- Volunteers
- 111 people
- Sponsor
- Promius Pharma, LLC
Breast Cancer, Early-stage Breast Cancer
Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
The purpose of this post-market, prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer.
- Conditions
- Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia
- Trial name
- NCT06215469
- Testing
- Amma Portable Scalp Cooling System (PSCS), Questionnaires
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
The goal of this interventional study is to determine if scalp cooling (by the Paxman Scalp Cooling System) reduces the extent and severity of alopecia in participants with advanced solid tumours receiving ADC.
- Conditions
- Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate, Alopecia
- Trial name
- SCARLET-ICE (NCT07474558)
- Testing
- scalp cooling, photographs via the Belle.AI app, Antibody-Drug Conjugates
- Where
- 3 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Jules Bordet Institute